147 related articles for article (PubMed ID: 1901298)
21. Control of mouse cumulus cell-oocyte complex integrity before and after ovulation: plasminogen activator synthesis and matrix degradation.
D'Alessandris C; Canipari R; Di Giacomo M; Epifano O; Camaioni A; Siracusa G; Salustri A
Endocrinology; 2001 Jul; 142(7):3033-40. PubMed ID: 11416025
[TBL] [Abstract][Full Text] [Related]
22. Modulation of plasminogen activator systems by matrix components in two breast cancer cell lines: MCF-7 and MDA-MB-231.
Pourreau-Schneider N; Delori P; Boutière B; Arnoux D; George F; Sampol J; Martin PM
J Natl Cancer Inst; 1989 Feb; 81(4):259-66. PubMed ID: 2492346
[TBL] [Abstract][Full Text] [Related]
23. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression.
Lockwood CJ; Krikun G; Papp C; Aigner S; Schatz F
J Clin Endocrinol Metab; 1995 Apr; 80(4):1100-5. PubMed ID: 7714076
[TBL] [Abstract][Full Text] [Related]
24. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer.
Nielsen BS; Sehested M; Timshel S; Pyke C; Danø K
Lab Invest; 1996 Jan; 74(1):168-77. PubMed ID: 8569179
[TBL] [Abstract][Full Text] [Related]
25. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
[TBL] [Abstract][Full Text] [Related]
26. Enhanced plasminogen activator production of Syrian hamster embryo cells transformed by chemicals or the c-Ha-ras oncogene: type of plasminogen activators involved and their contribution to the transformed phenotype.
de Kok AJ; Sips H; Chang GT; Verheijen JH
Carcinogenesis; 1989 Jul; 10(7):1155-61. PubMed ID: 2500266
[TBL] [Abstract][Full Text] [Related]
27. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
28. Clinical implications of urokinase and tissue type plasminogen activators and their inhibitor (PAI-1) in breast cancer tissue.
Luqmani YA; Temmim L; Parkar AH; Mathew M
Oncol Rep; 2002; 9(3):645-51. PubMed ID: 11956644
[TBL] [Abstract][Full Text] [Related]
29. [Estrogen dependent plasminogen activator in breast cancer cells; experimental and clinical studies].
Yamashita J; Inada K; Matsuo S; Kawano I; Misumi A; Akagi M
Nihon Geka Gakkai Zasshi; 1989 Nov; 90(11):1932-8. PubMed ID: 2514343
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.
Foekens JA; Schmitt M; van Putten WL; Peters HA; Bontenbal M; Jänicke F; Klijn JG
Cancer Res; 1992 Nov; 52(21):6101-5. PubMed ID: 1394237
[TBL] [Abstract][Full Text] [Related]
31. Mouse ovarian granulosa cells produce urokinase-type plasminogen activator, whereas the corresponding rat cells produce tissue-type plasminogen activator.
Canipari R; O'Connell ML; Meyer G; Strickland S
J Cell Biol; 1987 Aug; 105(2):977-81. PubMed ID: 3040774
[TBL] [Abstract][Full Text] [Related]
32. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis.
Ferrero-Poüs M; Hacène K; Bouchet C; Le Doussal V; Tubiana-Hulin M; Spyratos F
Clin Cancer Res; 2000 Dec; 6(12):4745-54. PubMed ID: 11156229
[TBL] [Abstract][Full Text] [Related]
33. Functional evaluation of plasmin formation in primary breast cancer.
Chappuis PO; Dieterich B; Sciretta V; Lohse C; Bonnefoi H; Remadi S; Sappino AP
J Clin Oncol; 2001 May; 19(10):2731-8. PubMed ID: 11352966
[TBL] [Abstract][Full Text] [Related]
34. Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
Schmitt M; Jänicke F; Graeff H
Blood Coagul Fibrinolysis; 1990 Dec; 1(6):695-702. PubMed ID: 2133250
[TBL] [Abstract][Full Text] [Related]
35. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.
De Cremoux P; Grandin L; Diéras V; Savignoni A; Degeorges A; Salmon R; Bollet MA; Reyal F; Sigal-Zafrani B; Vincent-Salomon A; Sastre-Garau X; Magdelénat H; Mignot L; Fourquet A;
Anticancer Res; 2009 May; 29(5):1475-82. PubMed ID: 19443353
[TBL] [Abstract][Full Text] [Related]
36. Plasminogen activators and cancer.
Duffy MJ
Blood Coagul Fibrinolysis; 1990 Dec; 1(6):681-7. PubMed ID: 2133247
[TBL] [Abstract][Full Text] [Related]
37. Urokinase plasminogen activator induces angiogenesis and tumor vessel invasion in breast cancer.
Hildenbrand R; Dilger I; Hörlin A; Stutte HJ
Pathol Res Pract; 1995 Jun; 191(5):403-9. PubMed ID: 7479358
[TBL] [Abstract][Full Text] [Related]
38. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
Look MP; van Putten WL; Duffy MJ; Harbeck N; Christensen IJ; Thomssen C; Kates R; Spyratos F; Fernö M; Eppenberger-Castori S; Sweep CG; Ulm K; Peyrat JP; Martin PM; Magdelenat H; Brünner N; Duggan C; Lisboa BW; Bendahl PO; Quillien V; Daver A; Ricolleau G; Meijer-van Gelder ME; Manders P; Fiets WE; Blankenstein MA; Broët P; Romain S; Daxenbichler G; Windbichler G; Cufer T; Borstnar S; Kueng W; Beex LV; Klijn JG; O'Higgins N; Eppenberger U; Jänicke F; Schmitt M; Foekens JA
J Natl Cancer Inst; 2002 Jan; 94(2):116-28. PubMed ID: 11792750
[TBL] [Abstract][Full Text] [Related]
39. Laminin and estradiol regulation of the plasminogen-activator system in MCF-7 breast-carcinoma cells.
Sonohara S; Mira-y-Lopez R; Brentani MM
Int J Cancer; 1998 Mar; 76(1):77-85. PubMed ID: 9533765
[TBL] [Abstract][Full Text] [Related]
40. Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
Jevrić M; Matić IZ; Krivokuća A; Đorđić Crnogorac M; Besu I; Damjanović A; Branković-Magić M; Milovanović Z; Gavrilović D; Susnjar S; Kisić Tepavčević D; Stanojković T
BMC Cancer; 2019 Jan; 19(1):71. PubMed ID: 30646864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
